Propanc Reports Preclinical Data For PRP In Chemoresistance; Phase 1 Set For Q1 '27
(RTTNews) - Propanc Biopharma Inc. (PPCB), a biopharmaceutical company, on Friday announced preclinical data for a formulation of pancreatic pro-enzymes (PRP) in treating pancreatic and ovarian cancer.
